Search

Displaying results 2581 - 2590 of 5419 in total
  1. Drug

    Gefitinib

    go.drugbank.com/drugs/DB00317
    ApprovedInvestigational

    It is marketed by AstraZeneca under the trade name Iressa.

  2. Drug

    5-androstenedione

    go.drugbank.com/drugs/DB01456
    ExperimentalIllicit

    Thus 5-androstenedione is a controlled substance, and its use in athletes is prohibited by The World Anti-Doping Agency. … Apart from the positioning of a carbon-carbon double bond, its structure is similar to [4-androstenedione], which is a prohormone which is naturally produced in the body by the adrenal glands and gonads

  3. Drug

    RUS 3108

    go.drugbank.com/drugs/DB05911
    Experimental

    RUS 3108 is being developed for the treatment of atherosclerosis, the major cause of cardiovascular disorders such as heart attacks and stroke by Dr. Reddy’s Laboratories.

  4. Drug

    Famprofazone

    go.drugbank.com/drugs/DB16702
    Experimental

    [L34724] It is important to note that the drug is metabolized to [methamphetamine] and [amphetamine] in the body and can lead to positive tests results for illicit drug use. … [A236369,L34724] Famprofazone is included in the list of prohibited substances specified by the ‘World Anti-Doping Agency’ (WADA).[L34729]

  5. Drug

    Sucralfate

    go.drugbank.com/drugs/DB00364
    ApprovedInvestigational

    It was approved by the FDA 1982 in tablet form, and in 1994 for the suspension form [L6073, L6076]. … It is considered a _cytoprotective agent_, protecting cells in the gastrointestinal tract from damage caused by agents such as gastric acid, bile salts, alcohol, and acetylsalicylic acid (aspirin), among

  6. Drug

    MVC-COV1901

    go.drugbank.com/drugs/DB15854
    Investigational

    Medigen has combined forces with Dynavax, which offers an advanced adjuvant, CpG 1018 (also known as [ISS-1018]), for use with its vaccine. … MVC-COV1901 is a vaccine candidate developed and commercialized by Medigen Vaccine Biologics Corporation. The vaccine candidate contains a perfusion form of the SARS-Cov2 recombinant spike protein.

  7. Drug

    GnRH pharmaccine

    go.drugbank.com/drugs/DB05815
    Experimental

    The pharmaccine is administered intramuscularly to the patient by injection and induces an immune response or production of antibodies in the patient, which neutralize GnRH thus removing it from circulation

  8. Drug

    Garetosmab

    go.drugbank.com/drugs/DB16379
    ApprovedInvestigational

    [L63940] By preventing this aberrant signaling, it reduces the formation of new abnormal bone.[L63940] It is administered by intravenous infusion every four weeks. … [L63940] Garetosmab-grts was approved by the FDA on August 19, 2026 to reduce the number of new heterotopic ossification lesions and clinician-assessed flare-ups in adults with FOP.

  9. Drug

    ALTU-135

    go.drugbank.com/drugs/DB05330
    Investigational

    ALTU-135 has been granted orphan drug and fast-track designation as well as CMA Pilot 2 program status by the Food and Drug Administration (FDA). … ALTU-135, the Company's orally administered enzyme replacement therapy for patients with pancreatic insufficiency, is manufactured by blending three drug substance enzymes: lipase, protease and amylase

  10. Drug

    Cefaloridine

    go.drugbank.com/drugs/DB09008
    ApprovedWithdrawn

    Cephaloridine or cefaloridine is a first generation semisynthetic cephalosporin. It is derived from cephalosporin C and is a zwitterion at physiological pH.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use